StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Pluvicto Global Growth in Constant Currencies by Year

Pluvicto Global Growth in Constant Currencies (% cc) (%)

Novartis Pluvicto Global Growth in Constant Currencies: 42.0% in FY2025, unchanged from a year earlier.

Latest, FY2025
42.0%
Period ended Dec 31, 2025
Change on a year earlier
0.0 pts
42.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Pluvicto | 1 994 | 1 392 | 43 | 42”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPluvicto Global Growth in Constant Currencies (% cc) (%)Year on yearSource
FY2025Dec 31, 202542.0%0.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 202442.0%-219.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
FY2023Dec 31, 2023261.0%–Novartis Form 6-K (0001370368-24-000007) ↗

Cite this data

StockData. (2026). Novartis Pluvicto Global Growth in Constant Currencies (%), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-pluvicto-yoy-cc-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.